The adenosine A2A receptor antagonist SCH58261 reduces macrophage/microglia activation and protects against experimental autoimmune encephalomyelitis in mice. 2019

Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
Department of Rehabilitation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS) affecting more than 2.5 million individuals worldwide. In the present study, myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) mice were treated with adenosine receptor A2A antagonist SCH58261 at different periods of EAE development. The administration of SCH58261 at 11-28 days post-immunization (d.p.i.) with MOG improved the neurological deficits. This time window corresponds to the therapeutic time window for MS treatment. SCH58261 significantly reduced the CNS neuroinflammation including reduced local infiltration of inflammatory cells, demyelination, and the numbers of macrophage/microglia in the spinal cord. Importantly, SCH58261 ameliorated the EAE-induced neurobehavioral deficits. By contrast, the SCH58261 treatment was ineffective when administered at the beginning of the onset of EAE (i.e., 1-10 d.p.i). The identification of the effective therapeutic window of A2A receptor antagonist provide insight into the role of A2A receptor signaling in EAE, and support SCH58261 as a candidate for the treatment of MS in human.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009186 Myelin Sheath The lipid-rich sheath surrounding AXONS in both the CENTRAL NERVOUS SYSTEMS and PERIPHERAL NERVOUS SYSTEM. The myelin sheath is an electrical insulator and allows faster and more energetically efficient conduction of impulses. The sheath is formed by the cell membranes of glial cells (SCHWANN CELLS in the peripheral and OLIGODENDROGLIA in the central nervous system). Deterioration of the sheath in DEMYELINATING DISEASES is a serious clinical problem. Myelin,Myelin Sheaths,Sheath, Myelin,Sheaths, Myelin
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011782 Quadriplegia Severe or complete loss of motor function in all four limbs which may result from BRAIN DISEASES; SPINAL CORD DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; or rarely MUSCULAR DISEASES. The locked-in syndrome is characterized by quadriplegia in combination with cranial muscle paralysis. Consciousness is spared and the only retained voluntary motor activity may be limited eye movements. This condition is usually caused by a lesion in the upper BRAIN STEM which injures the descending cortico-spinal and cortico-bulbar tracts. Quadriparesis,Spastic Quadriplegia,Tetraplegia,Flaccid Quadriplegia,Flaccid Tetraplegia,Paralysis, Spinal, Quadriplegic,Spastic Tetraplegia,Flaccid Quadriplegias,Flaccid Tetraplegias,Quadripareses,Quadriplegia, Flaccid,Quadriplegia, Spastic,Quadriplegias,Quadriplegias, Flaccid,Quadriplegias, Spastic,Spastic Quadriplegias,Spastic Tetraplegias,Tetraplegia, Flaccid,Tetraplegia, Spastic,Tetraplegias,Tetraplegias, Flaccid,Tetraplegias, Spastic
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004681 Encephalomyelitis, Autoimmune, Experimental An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) Autoimmune Encephalomyelitis, Experimental,Encephalomyelitis, Allergic,Encephalomyelitis, Experimental Autoimmune,Allergic Encephalomyelitis,Allergic Encephalomyelitis, Experimental,Autoimmune Experimental Encephalomyelitis,Experimental Allergic Encephalomyelitis,Experimental Autoimmune Encephalomyelitis,Encephalomyelitis, Autoimmune Experimental,Encephalomyelitis, Experimental Allergic,Experimental Allergic Encephalomyelitides,Experimental Encephalomyelitis, Autoimmune

Related Publications

Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
April 2022, International immunopharmacology,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
January 2018, Frontiers in immunology,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
December 2001, The Journal of experimental medicine,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
February 2022, Journal of neuroinflammation,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
November 2022, International immunopharmacology,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
April 2013, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
July 2017, Molecular neurobiology,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
December 1996, Circulation research,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
May 2024, Antioxidants & redox signaling,
Yu Chen, and Zheng-Xue Zhang, and Liu-Pu Zheng, and Li Wang, and Yin-Feng Liu, and Wei-Yong Yin, and Yan-Yan Chen, and Xin-Shi Wang, and Sheng-Tao Hou, and Jiang-Fan Chen, and Rong-Yuan Zheng
January 2017, Frontiers in pharmacology,
Copied contents to your clipboard!